ASICS GT-2160 'Black/Morpho' Delivers Bold Contrast and Retro Appeal
Name:ASICS GT-2160 'Black/Morpho'Colorway:'Black/Morpho'SKU:1203A275-003MSRP:$130 USDRelease Date:Available NowWhere to Buy:ASICS
TheASICSGT-2160receives a vibrant and intriguing addition with its new 'Black/Morpho' colorway. This iteration continues to pay homage to the technical design language of the GT-2000 series from the early 2010s, while its colorway draws inspiration from the striking black morpho tetra fish.
The silhouette combines a stealthy black mesh upper with vivid green and blue overlays, creating a bold visual contrast that highlights the shoe's intricate details. Metallic silver elements are strategically incorporated into the design, further elevating the visual appeal, all sitting atop an off-white sole unit that completes the dynamic look.
Emblematic features from the GT-2000 are also carried over, including a segmented midsole structure and visible GEL® technology inserts. This combination not only creates an industrial aesthetic but also provides advanced cushioning properties, enhancing comfort.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Inuvo Reaffirms 25% Q2 YOY Growth Guidance and Completes 1:10 Reverse Stock Split
LITTLE ROCK, Ark., June 12, 2025 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence-driven AdTech solutions, today announced that it was reaffirming its prior guidance that the Company was expecting revenue growth for the second quarter of not less than 25% on a year-over-year basis. The Company also completed a 1-for-10 reverse stock split of its outstanding common stock, as approved by shareholders at the Annual Meeting held on May 22, 2025. Inuvo's purpose in effectuating the reverse stock split is to improve the marketability and liquidity of its stock aiming to attract a broader range of institutional investors and analysts in support of its long-term growth strategy. Richard Howe, Chief Executive Officer of Inuvo, commented, 'Following two consecutive record-breaking quarters, we believe this strategic action will make our stock more accessible to institutional investors, many of whom are restricted from purchasing stocks trading below certain thresholds.' About Inuvo Inuvo®, Inc. (NYSE American: INUV) is a market leader in Artificial Intelligence built for advertising. Its IntentKey® AI solution is a first-of-its-kind proprietary and patented technology capable of identifying and actioning to the reasons why consumers are interested in products, services, or brands, not who those consumers are. To learn more, visit Safe Harbor / Forward-Looking Statements This press release includes certain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to qualify for the 'safe harbor' from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements include risks and uncertainties detailed in Inuvo, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, Inuvo's subsequent Quarterly Report on Form 10-Q for the period ended March 31, 2025, and Inuvo's other filings with the SEC. Inuvo cannot provide assurances that the assumptions upon which these forward-looking statements are based will prove to have been correct. Should one of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements, and investors are cautioned not to place undue reliance on these forward-looking statements, which are current only as of this date. Inuvo does not intend to update or revise any forward-looking statements made herein or any other forward-looking statements as a result of new information, future events or otherwise. Inuvo further expressly disclaims any written or oral statements made by a third party regarding the subject matter of this press release. Inuvo Company Contact: Wally Ruiz Chief Financial Officer Tel (501) 205-8508
Yahoo
40 minutes ago
- Yahoo
Barclays Announces the Redemption of 4 iPath® ETNs
NEW YORK, June 12, 2025--(BUSINESS WIRE)--Barclays Bank PLC ("Barclays") announced today that it will exercise its issuer call option and redeem in full each of the 4 series of iPath® ETNs (the "ETNs") listed in the table below on June 25, 2025 (the "Redemption Date"). Name of ETN BloombergTicker CUSIP/ISIN iPath® Bloomberg Livestock Subindex Total ReturnSM ETN COWTF 06739H743 /US06739H7439 iPath® Bloomberg Copper Subindex Total ReturnSM ETN JJCTF 06739F101 /US06739F1012 iPath® Bloomberg Grains Subindex Total ReturnSM ETN JJGTF 06739H305 /US06739H3057 iPath® Bloomberg Platinum Subindex Total ReturnSM ETN PGMFF 06739H255 /US06739H2554 After obtaining the requisite consents with respect to each series of ETNs in connection with Barclays' cash tender offer and consent solicitation, Barclays has amended the indenture and global certificate for each series of ETNs to provide Barclays with the right to redeem, in its sole discretion, all, but not less than all, of the outstanding ETNs of each series, on the Redemption Date. Please see the iPath® ETN website at (the "Information Page") for further details regarding the tender offer and consent solicitation. The "Valuation Date" for the redemption of each series of ETNs will be June 17, 2025, the fifth business day prior to the Redemption Date. A holder of the ETNs on the Redemption Date will receive a cash payment per ETN in an amount equal to the applicable Closing Indicative Note Value on the Valuation Date. For more information about how the Closing Indicative Note Value is determined, please refer to the section entitled "Terms and Conditions of the Offers and Consent Solicitations—Closing Indicative Note Value" in the Offer to Purchase and Consent Solicitation Statement dated December 7, 2023, as further supplemented, which is available on the Information Page. Under the terms of the ETNs, as amended, holders of any series of ETNs subject to issuer redemption will no longer have the option to exercise the holder redemption right. Therefore, no further elections for holder redemption will be accepted by Barclays. Holders of ETNs subject to issuer redemption may choose to continue to hold their ETNs until the Redemption Date or choose to sell their ETNs at a suitable time prior to that. Anyone considering investing in the ETNs or continuing to hold the ETNs should consider the risks described in the prospectus for the relevant series of ETNs when making an investment decision and consult with their broker or financial adviser to evaluate their investment in the ETNs. The pricing supplement and prospectus relating to each series of ETNs can be found on EDGAR, the SEC's website at as well as on the product website at the product page for each of the ETNs listed in the table above at An investment in the ETNs involves significant risks and may not be suitable for all investors. The ETNs are riskier than ordinary unsecured debt securities and do not benefit from any principal protection. For more information on risks associated with the ETNs, please see "Selected Risk Considerations" below and the risk factors included in the relevant pricing supplement. Barclays is the issuer of the ETNs and Barclays Capital Inc. is the issuer's agent in the distribution. Please contact Barclays for further questions: Financial advisors: Directly contact Barclays at etndesk@ or 1-212-528-7990 to obtain further information. Individual investors: Instruct your broker/advisor/custodian to email us at etndesk@ or to call us at: 1-212-528-7990. You may call in together with your broker/advisor/custodian or have them speak to us on your behalf. About Barclays Barclays is a British universal bank. We are diversified by business, by different types of customers and clients, and by geography. Our businesses include consumer banking and payments operations around the world, as well as a full-service corporate and investment bank. For further information about Barclays, please visit our website Selected Risk Considerations An investment in the ETNs described herein involves risks. Selected risks are summarized here, but we urge you to read the more detailed explanation of risks described under "Risk Factors" in the applicable prospectus supplement and pricing supplement. You May Lose Some or All of Your Principal: The ETNs are exposed to any change in the level of the underlying index or exchange rate, as applicable (the "index") between the inception date and the applicable valuation date. Additionally, if the level of the index is insufficient to offset the negative effect of the investor fee and other applicable costs, you will lose some or all of your investment at maturity or upon redemption, even if the level of such index has increased or decreased, as the case may be. The ETNs are riskier than ordinary unsecured debt securities and have no principal protection. Credit of Barclays Bank PLC: The ETNs are unsecured debt obligations of Barclays Bank PLC and are not, either directly or indirectly, an obligation of or guaranteed by any third party. Any payment to be made on the ETNs, including any payment at maturity or upon redemption, depends on the ability of Barclays Bank PLC to satisfy its obligations as they come due. As a result, the actual and perceived creditworthiness of Barclays Bank PLC will affect the market value, if any, of the ETNs prior to maturity or redemption. In addition, if Barclays Bank PLC were to default on its obligations, you may not receive any amounts owed to you under the terms of the ETNs. Market and Volatility Risk: The market value of the ETNs may be influenced by many unpredictable factors and may fluctuate between the date you purchase them and the maturity date or redemption date. You may also sustain a significant loss if you sell your ETNs in the secondary market. Factors that may influence the market value of the ETNs include prevailing market prices of the commodity markets, the U.S. stock markets or the U.S. Treasury market, the index components included in the underlying index, and prevailing market prices of options on such index or any other financial instruments related to such index; and supply and demand for the ETNs, including economic, financial, political, regulatory, geographical or judicial events that affect the level of such index or other financial instruments related to such index. Concentration Risk: Because the ETNs may be linked to an index composed of futures contracts on a single commodity or in only one commodity sector, the ETNs are less diversified than other funds. The ETNs can therefore experience greater volatility than other funds or investments. A Trading Market for the ETNs May Not Develop: The ETNs are not listed on any securities exchange and the liquidity of the ETNs may be limited. No Interest Payments from the ETNs: You may not receive any interest payments on the ETNs. Uncertain Tax Treatment: Significant aspects of the tax treatment of the ETNs are uncertain. You should consult your own tax advisor about your own tax situation. The ETNs may be sold throughout the day through certain brokerage accounts. Commissions may apply and there are tax consequences in the event of sale, redemption or maturity of ETNs. Sales in the secondary market may result in significant losses. © 2025 Barclays Bank PLC. All rights reserved. iPath, iPath ETNs and the iPath logo are registered trademarks of Barclays Bank PLC. All other trademarks, servicemarks or registered trademarks are the property, and used with the permission, of their respective owners. NOT FDIC INSURED · NO BANK GUARANTEE · MAY LOSE VALUE View source version on Contacts Press Contact:Ann Thielke+1 212 526
Yahoo
40 minutes ago
- Yahoo
Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
- GLIMPSE-1 model achieves state-of-the-art performance in antibody humanization and optimization, enabling scalable, structure-free biologic design from native human immune sequences ALAMEDA, Calif., June 12, 2025--(BUSINESS WIRE)--Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system. Infinimmune published results in a new bioRxiv preprint, demonstrating that GLIMPSE-1 can humanize clinical antibodies, engineer for affinity and developability parameters, and generate highly divergent functional variants, all through in silico design guided by the biology of the human adaptive immune system. "Fully human antibodies carry the evolutionary fingerprints of the human immune system, optimized over millions of years," said Wyatt McDonnell, Ph.D., Co-Founder and CEO, Infinimmune. "With GLIMPSE-1, we can decode and encode that logic directly from immune repertoires to discover and design better, safer biologics from day one. This approach complements the FDA's recent focus on assessing human-relevant methods for therapeutic development, which could ultimately benefit patients through more comprehensive safety assessment. We believe models like GLIMPSE-1 will remain essential in the discovery and development of modern antibody medicines." GLIMPSE-1 was developed as a core component of Infinimmune's therapeutic development capabilities, strengthening the company's pipeline of antibody drug candidates. The model was trained using a large, diverse dataset with proprietary sequences from Infinimmune's Complete Human® and Anthrobody® technologies, which source antibodies directly from native human repertoires, allowing it to learn the biological and functional constraints of human immunity. Key results from the preprint include: Best-in-class performance in antibody humanization benchmarks compared to nine leading antibody language models Successful affinity optimization across multiple targets, producing sub-nanomolar variants while addressing developability concerns Creation of highly divergent functional antibody variants with <90% sequence identity to parent sequences Species cross-reactivity engineering across human, cynomolgus monkey, and murine targets Engineering for formulation-preferred parameters such as isoelectric point while maintaining binding affinity GLIMPSE-1 operates entirely in human antibody sequence space, predicting viable antibody variants without 3D structure modeling, energy calculations, or experimental screening beforehand. The resulting antibodies maintain essential functional properties and characteristics consistent with clinically approved monoclonal antibodies, all guided by patterns learned from human immune systems. The development of GLIMPSE-1 aligns with recent FDA initiatives exploring human-relevant methodologies for therapeutic development. The FDA's roadmap for integrating New Approach Methodologies (NAMs) identifies monoclonal antibodies as an initial focus area, creating an environment where human-first models like GLIMPSE-1 may provide valuable complementary insights. Infinimmune has successfully integrated GLIMPSE-1 into its therapeutic antibody development pipeline, where the model has significantly contributed to the engineering and optimization of the company's lead programs. The company is currently exploring strategic partnerships with pharmaceutical and biotechnology companies to apply GLIMPSE-1's capabilities to partner's therapeutic programs. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit and follow us on LinkedIn and @infinimmune. View source version on Contacts Media Kimberly HaKKH
